Form 4: Cidara Therapeutics Director Acquires Stock Options

Theodore R. Schroeder, a director of Cidara Therapeutics, acquired stock options exercisable for 2,125 shares of common stock on July 18, 2024.

Summary

• On July 18, 2024, Theodore R. Schroeder, a director of Cidara Therapeutics, Inc., acquired stock options.
• These options allow him to purchase 2,125 shares of the company's common stock at an exercise price of $12.64 per share.
• The options vest on the earlier of the first anniversary of the grant date or the day before the Issuer's 2025 annual meeting of stockholders.
• The options expire on July 17, 2034.
• Following this transaction, Schroeder directly owns 2,125 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a director's acquisition of stock options. It doesn't inherently convey strong positive or negative sentiment.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates